Reports the effectiveness of topical hypericin for early-stage cutaneous T-cell lymphoma, suggesting it may enhance patient quality of life.
Topical synthetic hypericin is a significant advancement for early-stage CTCL. Its excellent safety profile, proven efficacy, and non-mutagenic mechanism position it as a valuable first-line option. Minimal local adverse events and limited systemic absorption offer a key long-term safety advantage over conventional phototherapies. Its effectiveness in both patch and plaque lesions makes it a versatile tool, improving outcomes and quality of life for patients.
No takes yet. Share an insight, caveat, or question.
Poligone et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: